Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa.

To be part of this study, you would need to be an adult (18 years or older) with a clear diagnosis of moderate to severe hidradenitis suppurativa (HS). Importantly, your doctor must have already decided that treatment with secukinumab is the right choice for you, and you would be starting this medicine as part of your usual care, not because of the study itself. You also need to agree in writing to let your medical information be collected for the study.

There are also some reasons why you wouldn't be able to join. For example, if you have certain other health conditions like inflammatory bowel disease (Crohn's disease or ulcerative colitis), or if you're taking part in another research study at the same time, this study wouldn't be suitable for you. Also, if you've already been treated with certain other types of biologic medicines (like IL-17 inhibitors or other biologics if you haven't had them before), you wouldn't be eligible.

Basically, if secukinumab is already medically indicated for your HS and you're about to start it, and you don't have any of the specific conditions mentioned that would prevent you from taking it, then you might be able to participate.

If you decide to take part, you would be receiving secukinumab as your doctor has prescribed for your hidradenitis suppurativa, just as you would if you weren't in the study. The study doesn't involve any extra or different treatments. Instead, researchers will simply be collecting information about your health and your secukinumab treatment during your regular clinic visits over a two-year period. This means they'll gather details on how your condition is progressing, how often you take your medication, and any changes your doctor makes to your treatment plan. The study simply observes what's already happening with your care.